More MS news articles for March 2000

NeuralStem Issued Additional Claims for In Vitro Generation of Differentiated Neurons from Culture of Mammalian Multipotential Neural Stem Cells

Thursday March 23, 6:59 am Eastern Time
Company Press Release
SOURCE: NeuralStem BioPharmaceuticals, Ltd.

COLLEGE PARK, Md., March 23 /PRNewswire/ -- NeuralStem BioPharmaceuticals, Ltd. today announced the issuance on March 21 of U.S. Patent No. 6,040,180 by the U.S. Patent & Trademark Office. This patent grants additional claims on the Company's proprietary neural stem cell technology, expanding on its previously issued U.S. Patent No. 5,753,506.

The Company's original patent covers a broad platform of claims encompassing the isolation, propagation, and controlled differentiation in culture of multipotential stem cells from all regions of the human brain and spinal cord, their derivatives, and their uses and products by process. The expanded claims announced today cover NeuralStem's proprietary methods for differentiating central nervous system (CNS) stem cells into specific types of neurons, such as dopamine-producing neurons, acetylcholine-producing neurons, GABAergic neurons, and regionally specific neurons such as spinal cord neurons from the spinal cord.

"We have developed the ability to produce, with precision and predictability, both the type and number of nerve cells desired -- for example, dopamine-producing neurons for treating patients suffering from Parkinson's disease," said I. Richard Garr, President and CEO of NeuralStem. "These claims mark another milestone toward achieving one of our main goals -- development of dedicated cell banks for therapeutic application to specific diseases -- and build on NeuralStem's intellectual property and leadership positions as we work to usher in a new era of cell-based therapies for treating and curing neurodegenerative disorders."

Disorders of the central nervous system, including Parkinson's disease, Alzheimer's disease, stroke, and spinal cord injuries, affect more people than any other category of disease, and there are currently few or no effective treatments available. The enormous health care costs associated with these conditions are projected to increase dramatically with the aging of the population. The transplantation of CNS stem cells to replace damaged or diseased nerve tissue and restore neural function is widely regarded as a most promising new approach to treatment. NeuralStem is developing a precisely controlled system for producing expandable and renewable supplies of standardized, optimized human brain and spinal cord neurons in commercial quantities to provide healthy replacement cells for patients suffering from these conditions.

NeuralStem Biopharmaceuticals, Ltd. is a privately held company focused on the discovery, development, and commercialization of a new generation of biotherapeutic products and technologies to treat and cure neurodegenerative disorders of the brain and spinal cord, based on the Company's patented CNS stem cell technology and human neurons derived from CNS stem cells. NeuralStem's target conditions include Parkinson's disease, Alzheimer's disease, depression, stroke, schizophrenia, multiple sclerosis, epilepsy, and spinal cord injury.

Contact: Richard Garr, President & CEO of NeuralStem Biopharmaceuticals, 301-571-9323, or; or Mary Moynihan or Alex Friend, both of M2 Life Sciences Communications, 202-726-4800

SOURCE: NeuralStem BioPharmaceuticals, Ltd.